Tern appoints Jane McCracken & Iain Ross as independent Non-Executive Directors

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced a number of changes to the Company’s Board of Directors.  Tern is pleased to announce the appointment of Jane Karwoski (known as “Jane McCracken”) and Iain Ross as independent Non-Executive Directors of the Company with immediate effect.  Sarah Payne and Alan Howarth have stepped down from the Board with immediate effect to concentrate on their other business interests.

Following these changes the Board now comprises Ian Ritchie (Non-Executive Chairman), Jane McCracken (Non-Executive Director) and Iain Ross (Non-Executive Director).

Jane McCracken has spent her career working with high growth technology businesses based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor. Her experience covers a variety of areas including software, e-commerce, digital health and clinical research.  She recently served as an Entrepreneur-in-Residence at the Advanced Technology Development Center, the state incubator based at Georgia Institute of Technology.  She is the Chief Growth Officer for Corps Team, a US-based search and staffing firm supporting startups to the Fortune 500.  Jane also serves on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment Trust plc, which invests globally in high growth companies; and Radyus Research, a US-based privately held company that advises on drug discovery, lead candidate selection, and enabling studies.

Iain Ross has over 40 years’ experience in the international life sciences and technology sectors and has held significant roles in multi-national pharmaceutical and biotech companies.  He has completed multiple financing transactions and has over 30 years’ experience in cross-border management as a chairman or CEO.  He has led or participated in eight IPOs and has direct experience of M&A transactions in Europe, the USA and the Pacific Rim.  Currently he is Chairman of NASDAQ listed Silence Therapeutics plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-executive director roles. 

Further information on Jane McCracken and Iain Ross disclosed in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is set out below.

Commenting, Ian Ritchie, Chairman of Tern, said: “I am delighted to welcome Jane and Iain to the Tern Board.  I believe their skills and experience will be invaluable as we focus on generating returns for our shareholders from realisations.  I would also like to take this opportunity to thank Sarah and Alan for their significant contributions to Tern and wish them well for the future.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search